United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
2024-10-04 10:00:00 PM
|
Chg.
+5.8600
|
Volume |
Bid10:24:27 PM |
Ask10:24:27 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
355.9300USD
|
+1.67%
|
153,736 Turnover: 24.68 mill. |
314.0000Bid Size: 100 |
361.0000Ask Size: 200 |
15.84 bill.USD |
- |
16.92 |
Business description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Management board & Supervisory board
CEO |
Dr. Martine A. Rothblatt |
Management board |
James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
Supervisory board |
Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson, Jan Malcolm |
Company data
Name: |
United Therapeutics Corporation |
Address: |
1000 Spring Street,Silver Spring, Maryland 20910, USA |
Phone: |
+1-301-608-9292 |
Fax: |
- |
E-mail: |
-
|
Internet: |
https://www.unither.com/index |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
12-31 |
Free Float: |
- |
IPO date: |
1999-06-17 |
Investor relations
Name: |
- |
IR phone: |
+1-301-608-9292 |
IR Fax: |
- |
IR e-mail: |
-
|
Main Shareholders
Freefloat |
|
61.80% |
BlackRock, Inc |
|
9.60% |
The Vanguard Group |
|
8.90% |
Renaissance Technologies LLC |
|
8.10% |
Avoro Capital Advisors LLC |
|
6.40% |
FMR, LLC |
|
5.20% |